Israel's ReWalk Plans IPO After 'Ecoskeleton' Success by the Forward

Israel's ReWalk Plans IPO After 'Ecoskeleton' Success

The Israeli company ReWalk Robotics will sell public shares for the first time for a device that enables people with spinal cord injuries to stand and walk.

The company, which changed its name from Argo Medical Technologies to the name of its major product, announced this week that it will make an initial public offering on the NASDAQ next month.

The ReWalk device, a 44-pound exoskeleton that allows individuals with spinal cord injuries to walk, stand and sit with minimal exertion, was featured in 2010 on the popular television drama “Glee” while undergoing clinical trials in the United States.

The company recently received approval for the device from the U.S. Food and Drug Administration for home use. It is already in use in Europe.

The ReWalk, developed by Argo and released in September 2012, is the brainchild of Amit Goffer, an Israeli computer scientist and inventor who became paralyzed after a 1997 car accident. Although he cannot use the ReWalk himself because he lacks the use of his arms, he began designing the device with the help of a $50,000 grant from the Israeli government because he was frustrated at the lack of alternatives to a wheelchair.

The device functions through motors attached to the legs that can propel a disabled person at a slow walking speed. A tilt sensor, the same technology used on Segway electric transporters, can sense whether the user wants to move forward or back, stand or sit. Poles are used for added support.


Israel's ReWalk Plans IPO After 'Ecoskeleton' Success

Your Comments

The Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. All readers can browse the comments, and all Forward subscribers can add to the conversation. In the interest of maintaining a civil forum, The Forward requires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not and will be deleted. Egregious commenters or repeat offenders will be banned from commenting. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and the Forward reserves the right to remove comments for any reason.

Recommend this article

Israel's ReWalk Plans IPO After 'Ecoskeleton' Success

Thank you!

This article has been sent!